Abstract: |
| OS ANALYSIS BY TREATMENTS RECEIVED AFTER TRABECTEDIN/PLD OR PLD ALONE IN PATIENTS WITH RECURRENT OVARIAN CANCER: PLATINUM VS NON-PLATINUM . |
| Background and Aims: Platinum-resistance mechanism in ovarian cancer is multifactorial. At lower resistance levels, DNA repair through the nucleotide excision repair (NER) pathway is the primary mechanism of cellular resistance; at higher level glutathione metabolism appears to be the most important pathway (Saldivar, Gynecol Oncol 2007). Trabectedin may lead to increased sensitivity to subsequent platinum through its interaction with NER (Colmegna, BJC 2015). We retrospectively evaluated results of patients with ROC treated with trabectedin/PLD or PLD in the randomized phase III OVA-301 (Monk JCO 2009) and followed by platinum vs. non-platinum treatment to investigate if the molecular hypothesis of the synergistic effect of trabectedin/PLD followed by platinum correlates with OS results previously obtained. Methods: An exploratory OS analysis, counted from the administration of trabectedin/PLD or PLD, was performed in patients with a PFI from 0-6 and 6-12 months, who received subsequent treatment in OVA-301. Results in platinum-resistanbt patients were further analysed depending on resistance level. Results: Trabectedin/PLD followed by platinum resulted in statistically significant improvement on OS in both groups (Table 1). In platinum-resistant patients, differences were mainly observed in patients relapsing between 3 and 6 months (Table 2). No significant differences with PLD were observed in either group.   Conclusions: Results suggest that using trabectedin/PLD followed by platinum (vs. non-platinum) may prolong survival due to potential re-sensitization to platinum rechallenge. This may result from trabectedin’s interaction with NER machinery, which plays a key role in the development of intermediate levels of platinum resistance. These hypothesis-generating data are being currently investigated in a prospective phase III study. |
CAMBIO DE DISCURSO : ADIÓS A LA SEGUNDA LÍNEA SCLC-ES EN EEUU Y EN EU ...CAMBIAMOS DISCURSO A MANTENIMIENTO EN FIRTS-LINE /// SI NO EXISTIERA IMFORTE ... AHORA MISMO PHARMAMAR ESTARÍA ANTE UNA GRAVE SITUACIÓN /// IMFORTE EN EU DE UN TAM DE 600 MILLONES A UN MERCADO REAL MUCHO MENOR QUE PODRÍA SER DE TAN SOLO UNOS 85 MILLONES /// 2 DE OCTUBRE DE 2028 ... ES LA FECHA PARA LA POSIBLE ENTRADA DE GENÉRICOS DE LURBINECTEDIN ...